Recently, the specialized training program “Professional Lawyer Training Course for the Biopharmaceutical Industry,” hosted by the Tianjin Lawyers Association and organized by Zhihe, was successfully held. Attorney Su Zhongming, Director of the Compliance Practice Center at Beijing Starrise Law Firm, was invited to serve as a distinguished guest lecturer, delivering an in-person session on the topic of “Criminal Risk Prevention in Commercial Bribery within the Pharmaceutical Industry.” His presentation provided local Tianjin‑based practicing lawyers with expert insights that combined practical depth and industry‑specific relevance.
This training program is a specialized initiative launched by the Tianjin Lawyers Association to enhance legal service capabilities in the biopharmaceutical sector. It aims to establish a systematic learning platform for local attorneys in the field of industry compliance, thereby strengthening their expertise in supporting pharmaceutical companies’ compliance‑related initiatives. Drawing on his extensive practical experience in corporate compliance and legal services for the pharmaceutical industry, Attorney Su Zhongming has been appointed as a specially invited lecturer for this program and has received an official letter of appointment from the Tianjin Lawyers Association, in recognition of his professional support and contributions to this industry‑wide talent‑development effort.
Su Zhongming Director of the Compliance Practice Center at Beijing Starrise Law Firm
During the training, Attorney Su Zhongming provided a professional analysis of the criminal risks associated with commercial bribery in the pharmaceutical industry and corresponding preventive strategies, organized around four core modules. First, he systematically reviewed the overarching regulatory trends governing anti‑commercial bribery in the sector, helping participating lawyers develop a comprehensive understanding of the industry’s regulatory landscape. Next, he conducted a clause‑by‑clause breakdown and in-depth interpretation of key regulations and policies relevant to commercial bribery in the pharmaceutical field, clarifying the boundaries of applicable rules. Following that, he engaged in targeted analyses based on typical business scenarios in the industry, identifying high‑frequency risk areas and issuing specific advisory notes. Finally, moving to the practical implementation level, he shared end‑to‑end preventive strategies for managing legal risks related to commercial bribery within pharmaceutical companies.
This training program was entirely focused on practical challenges, eschewing unnecessary theoretical exposition; all content was closely aligned with the real‑world needs of frontline lawyers handling compliance matters for pharmaceutical companies. Participants widely reported that the course effectively addressed their knowledge gaps in areas such as pharmaceutical commercial bribery and compliance framework development for healthcare enterprises, while also laying a solid foundation for continued exchanges and collaboration between the legal professions in Beijing and Tianjin in the fields of digital rule of law and industry‑specific compliance. Moving forward, Xinglai Law Firm will continue to engage in professional‑training initiatives organized by bar associations across the country, sharing its extensive practical expertise in corporate compliance and industry‑specific legal services.
Editor and Layout: Wang Xin
Reviewed by: Shen Xinyu
Beijing Headquarters Address: No. 8, Jianguomen North Street, Dongcheng District, Beijing 17th Floor, China Resources Building
Contact numbers: 010-64011566, 18811162996
Wuhan Branch Address: Room 1001, 10th Floor, Huangpu International Center, Jiang’an District, Wuhan, Hubei Province
Contact number: 027-82288828
Hefei Branch Address: Rooms 1703–1710, Building E, Weilan Business Harbor, No. 188 Qianshan Road, Shushan District, Hefei, Anhui Province
Contact numbers: 0551-68127192, 15850561916
Related News
2026-11-12